Effects of celecoxib and Ly117018 combination on human breast cancer cells in vitro

Breast Cancer: Basic and Clinical Research

Volumn 3, Issue 1, 2009, Pages 23-34

  Baumann, Klaus H ^a   Klusmeier, Elmar ^a   Eggemann, Isabel ^a   Reinartz, Silke ^a   Almeroth, Achim ^a   Kalder, Mathias ^a   Wagner, Uwe ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Celecoxib; COX 2; Drug synergism; Estrogen receptor; Ly117018; SERM

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; CELECOXIB; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; PROTEIN KINASE B;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 77953466992     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/bcbcr.s2291     Document Type: Article

References (79)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;ii:104-107
2. Dickson RB, Thompson EW, Lippman ME. Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol. 1990;37:305-316
3. Clarke R, Skaar T, Baumann K, et al. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat. 1994;31:237-248 (Pubitemid 24323465)
4. Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab. 2004;15:316-323 (Pubitemid 39180006)
5. Simpson PT, Reis-Filho JS, Gale T, et al. Molecular evolution of breast cancer. J Pathol. 2005;205:248-254
6. Butt AJ, McNeil CM, Musgrove EA, et al. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 2005;(12 Suppl 1):S47-59.
7. Rodrik V, Zheng Y, Harrow F, et al. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol. 2005;25:7917-7925 (Pubitemid 41170149)
8. Merkel DE, Osborne CK. Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989;3:641-652
9. Chen WY, Colditz GA. Risk factors and hormone-receptor status: epidemiology, risk-prediction models. Nat Clin Pract Oncol. 2007;4:415-423
10. Jordan VC. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol. 2006;147:S269-76.
11. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis. Mutat Res. 2005;591:247-263 (Pubitemid 41654853)
12. Schiff R, Massarweh SA, Shou J, et al. Advanced concepts in estrogen receptor biology and breast cancer endocrine. Cancer Chemother Pharmacol. 2005;1:10-20.
13. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006;(13 Suppl 1):S15-24. (Pubitemid 46219245)
14. Riggins RB, Schrecengost RS, Guerrero MS, et al. Pathways to tamoxifen resistance. Cancer Lett. 2007;256:1-24.
15. Robertson JF. Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev. 2004;30:695-706. (Pubitemid 39497155)
16. Diez-Perez A. Selective estrogen receptor modulators (SERMS). Arq Bras Endocrinol Metabol. 2006;50:720-734 (Pubitemid 44786008)
17. Freiss G, Galtier F, Puech C, et al. Anti-growth factor activities of benzothiophenes in human breast cancer cells. J Steroid Biochem Mol Biol. 2005;94:451-460 (Pubitemid 40616406)
18. Ariazi EA, Ariazi JL, Cordera F, et al. Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 2006;6:181-202.
19. Adamo V, Iorfi da M, Montalto E, et al. Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol. 2007;18:vi53-7.
20. Rugo HS. Hormonal therapy for advanced breast cancer. Hematol Oncol Clin North Am. 2007;21:273-291 (Pubitemid 46754736)
21. Westley BR, Holzel F, May FE. Effects of oestrogen and the antioestrogens, tamoxifen and LY117018, on four oestrogen-regulated RNAs in the EFM-19 breast cancer cell line. J Steroid Biochem. 1989;32:365-372 (Pubitemid 19099153)
22. Jordan VC, Brodie AMH. Development and evolution of therapies targeted to the estrogen receptor for the. Steroids. 2007;72:7-25.
23. Lykkesfeldt AE. Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer. Acta Oncol. 1996;5:9-14. (Pubitemid 27076977)
24. Gururaj AE, Rayala SK, Vadlamudi RK, et al. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res. 2006;12:1001s-7s.
25. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006;232:123-138
26. Gianni L. The future of targeted therapy: combining novel agents. Oncology. 2002;(63 Suppl 1):47-56.
27. Caponigro F, Basile M, de Rosa V, et al. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs. 2005;16:211-221 (Pubitemid 40250618)
28. Huang J, Li X, Hilf R, et al. Molecular basis of therapeutic strategies for breast cancer. Curr Drug Targets Immune. Endocr Metabol Disord. 2005;5:379-396
29. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-2743 (Pubitemid 46021510)
30. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic. Clin Cancer Res. 2006;12:3124-3129 (Pubitemid 44044010)
31. Akagi T, Murata K, Shishido T, et al. v-Crk activates the phosphoinositide 3-kinase/AKT pathway by utilizing focal adhesion kinase and H-Ras. Mol Cell Biol. 2002;22:7015-7023
32. Bellacosa A, Testa JR, Moore R, et al. A portrait of AKT kinases: human cancer and animal models depict a family with. Cancer Biol Ther. 2004;3:268-275
33. Fujita N, Tsuruo T. Survival-signaling pathway as a promising target for cancer chemotherapy. Cancer Chemother Pharmacol. 2003; (52 Suppl 1):S24-8. (Pubitemid 37047020)
34. Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7. Mol Pathol. 2001;54:149-154
35. Song RX, Santen RJ. Membrane initiated estrogen signaling in breast cancer. Biol Reprod. 2006;75:9-16. (Pubitemid 43946335)
36. Stoica GE, Franke TF, Moroni M, et al. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. Oncogene. 2003;22:7998-8011. (Pubitemid 37175864)
37. Mazhar D, Ang R,Waxman J. COX inhibitors and breast cancer. Br J Cancer. 2006;94:346-350
38. Guastalla JP, Bachelot T, Ray-Coquard I. [Cyclooxygenase 2 and breast cancer. From biological concepts to therapeutic trials]. Bull Cancer. 2004;91 Spec No:S99-108.
39. Brueggemeier RW, Richards JA, Petrel TA. Aromatase and cyclooxygenases: enzymes in breast cancer. J Steroid Biochem Mol Biol. 2003;86:501-507 (Pubitemid 37412590)
40. Leonessa F, Jacobson M, Boyle B, et al. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res. 1994;54:441-447 (Pubitemid 24979992)
41. Brunner N, Boysen B, Jirus S, et al. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997;57:3486-3493 (Pubitemid 27355496)
42. Tallarida RJ. The interaction index: a measure of drug synergism. Pain. 2002;98:163-168
43. Abramoff M, 2006. Getting started with Image J. http://rbp.fmrp.usp.br/ downloads/gettingstartedimagej-feb2006.pdf
44. Rasband W. 2006. Image J Software. http://rsb.info.nih.gov/ij/download. html.
45. Scholl SM, Huff KK, Lippman ME. Antiestrogenic effects of LY 117018 in MCF-7 cells. Endocrinology. 1983;113:611-617
46. Coradini D, Biffi A, Cappelletti V, et al. Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells. Anticancer Res. 1994;14:1059-1064 (Pubitemid 24272567)
47. Liby K, Rendi M, Suh N, et al. The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. Clin Cancer Res. 2006;12:5902-5909 (Pubitemid 44629624)
48. Strohmeier R, Roller M, Sanger N, et al. Modulation of tamoxifeninduced apoptosis by peripheral benzodiazepine receptor ligands in breast cancer cells. Biochem Pharmacol. 2002;64:99-107. (Pubitemid 34775180)
49. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically downregulate signal transduction and. Anticancer Res. 1999;19:1657-1662
50. Mabuchi S, Ohmichi M, Kimura A, et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase. Endocrinology. 2004;145:1302-1313
51. Werner HM, Franke HR, Vermes I. Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs. Climacteric. 2005;8:294-299 (Pubitemid 41224442)
52. Tari AM, Simeone AM, Li YJ, et al. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab Invest. 2005;85:1357-1367
53. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem. 2006;6:221-232
54. Su B, Landini S, Davis DD, et al. Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem. 2007;50:1635-1644 (Pubitemid 46564383)
55. Badawi AF, Badr MZ. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma and levels of prostaglandin E2 and 15-deoxy-delta12,14-prostaglandin J2 in human breast cancer and metastasis. Int J Cancer. 2003;103:84-90.
56. Half E, Tang XM, Gwyn K, et al. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res. 2002;62:1676-1681 (Pubitemid 34408488)
57. Boland GP, Butt IS, Prasad R, et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer. 2004;90:423-429 (Pubitemid 38250640)
58. Subbaramaiah K, Norton L, Gerald W, et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277: 18649-18657 (Pubitemid 34952420)
59. Witton CJ, Hawe SJ, Cooke TG, et al. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004;45:47-54.
60. Shim V, Gauthier ML, Sudilovsky D, et al. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 2003; 63:2347-2350 (Pubitemid 36605165)
61. Zhao X, Goswami M, Pokhriyal N, et al. Cyclooxygenase-2 expression during immortalization and breast cancer progression. Cancer Res. 2008;68:467-475
62. Pan MR, Hou MF, Chang HC, et al. Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem. 2008;283:11155-11163
63. Robertson FM, Mallery SR, Bergdall-Costell VK, et al. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts. Anticancer Res. 2007;27:719-727
64. Witters LM, Myers A, Lipton A. Combining fl avopiridol with various signal transduction inhibitors. Oncol Rep. 2004;11:693-698
65. Benoit V, Relic B, Leval Xd X, et al. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene. 2004;23:1631-1635 (Pubitemid 38406527)
66. van Wijngaarden J, van Beek E, van Rossum G, et al. Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer. 2006;43:433-442 (Pubitemid 46123984)
67. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci. 1999;889:84-86 (Pubitemid 30040428)
68. Basu GD, Pathangey LB, Tinder TL, et al. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005;7: R422-35.
69. Kucab JE, Lee C, Chen CS, et al. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res. 2005;7:R796-807.
70. Stuart EC, Rosengren RJ. The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells. Life Sci. 2008;82:943-948
71. Jordan NJ, Gee JM, Barrow D, et al. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Res Treat. 2004;87:167-180 (Pubitemid 39237793)
72. St-Germain ME, Gagnon V, Mathieu I, et al. AKT regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol. 2004;24:1311-1324
73. Ding H, Han C, Zhu J, et al. Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. Int J Cancer. 2004;113:803-810 (Pubitemid 40101263)
74. Li Z, Li J, Mo B, et al. Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol. 2008;24:401-409
75. Villani MG, Appierto V, Cavadini E, et al. 4-oxo-fenretinide, a recently identifi ed fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res. 2006;66:3238-3247
76. Cerchietti LC, Bonomi MR, Navigante AH, et al. Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. J Neurooncol. 2005;71:73-81.
77. Harris RE, Beebe-Donk J, Alshafi e GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006;6:27. (Pubitemid 43264309)
78. Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004;10:4062-4067 (Pubitemid 38812482)
79. Canney PA, Machin MA, Curto J. A feasibility study of the effi cacy and tolerability of the combination of Exemestane with the COX-2 inhibitor Celecoxib in post-menopausal patients with advanced breast cancer. Eur J Cancer. 2006;42:2751-2756 (Pubitemid 44584673)